Trials / Withdrawn
WithdrawnNCT04880369
Phytoestrogens and Breast Cancer - Effects of Phytoestrogens on Markers of Disease Progression and Gene Expression
DAGMAR: Phytoestrogens and Breast Cancer - Effects of Phytoestrogens on Markers of Disease Progression and Gene Expression
- Status
- Withdrawn
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Danish Cancer Society · Academic / Other
- Sex
- Female
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The aim is to investigate if soy isoflavones and lignans affect markers of disease progression and gene expression among breast cancer patients receiving neo-adjuvant treatment in a three arm, double-blinded, randomized placebo-controlled trial (RCT) comparing: soy isoflavone supplementation, lignan supplementation, and placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Soy isoflavones | Commercially available dietary supplement (capsule) containing 60 mg isoflavones (genistein, daidzein and glycitein). |
| DIETARY_SUPPLEMENT | Lignans | Commercially available dietary supplement (capsule) containing 63 mg lignans (secoisolaricirecinol) |
| DIETARY_SUPPLEMENT | Placebo | The placebo capsules are supplied and packaged by Region Hovedstadens Apotek (Denmark) and will contain lactose monohydrate, potato starch, gelatin, magnesium stearate and talc. |
Timeline
- Start date
- 2021-03-01
- Primary completion
- 2022-07-01
- Completion
- 2022-12-01
- First posted
- 2021-05-10
- Last updated
- 2024-08-07
Source: ClinicalTrials.gov record NCT04880369. Inclusion in this directory is not an endorsement.